This HTML5 document contains 90 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dbpedia-dehttp://de.dbpedia.org/resource/
dctermshttp://purl.org/dc/terms/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n18https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n11http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n14https://druginfo.nlm.nih.gov/drugportal/name/
n16http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Tirbanibulin
rdf:type
dbo:Drug owl:Thing n11:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386
rdfs:label
Tirbanibulin Tirbanibulin
rdfs:comment
Tirbanibulin, sold under the brand name Klisyri, is a medication for the treatment of actinic keratosis (AKs) on the face or scalp. The most common side effects include local skin reactions, application site pruritus, and application site pain. Tirbanibulin was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Tirbanibulin, vermarktet unter dem Markennamen Klisyri (Almirall), ist ein Arzneistoff zur Behandlung von aktinischer Keratose im Gesicht oder auf der Kopfhaut. Es wirkt als Mitosehemmer.
foaf:depiction
n16:Tirbanibulin-line.png
dcterms:subject
dbc:Pyridines dbc:Ethers dbc:Amides dbc:Morpholines
dbo:wikiPageID
66118142
dbo:wikiPageRevisionID
1103124669
dbo:wikiPageWikiLink
dbc:Morpholines dbc:Pyridines dbr:Tubulin dbr:Medication dbc:Ethers dbc:Amides dbr:European_Medicines_Agency dbr:Microtubule_inhibitor dbr:Topical_administration dbr:Tyrosine-protein_kinase_CSK dbr:First-in-class_medication dbr:Food_and_Drug_Administration dbr:Mitotic_inhibitor dbr:Actinic_keratosis dbr:Indication_(medicine) dbr:Committee_for_Medicinal_Products_for_Human_Use
dbo:wikiPageExternalLink
n14:tirbanibulin
owl:sameAs
wikidata:Q27888424 dbpedia-de:Tirbanibulin n18:2bh6i
dbp:wikiPageUsesTemplate
dbt:Cite_web dbt:Infobox_drug dbt:Reflist dbt:Use_dmy_dates dbt:Portal_bar dbt:ClinicalTrialsGov dbt:Use_American_English dbt:Antibiotics_and_chemotherapeutics_for_dermatological_use dbt:Short_description
dbo:thumbnail
n16:Tirbanibulin-line.png?width=300
dbp:atcSuffix
BX03
dbp:atcPrefix
D06
dbp:c
26
dbp:casNumber
897016
dbp:chembl
571546
dbp:chemspiderid
24633341
dbp:class
dbr:Microtubule_inhibitor
dbp:drugbank
DB06137
dbp:h
29
dbp:iupacName
N-benzyl-2-[5-[4-phenyl]pyridin-2-yl]acetamide
dbp:kegg
D11691
dbp:legalUs
Rx-only
dbp:n
3
dbp:o
3
dbp:pubchem
23635314
dbp:routesOfAdministration
dbr:Topical_administration
dbp:smiles
O=CNCc1ccccc1
dbp:stdinchi
1
dbp:stdinchikey
HUNGUWOZPQBXGX-UHFFFAOYSA-N
dbp:synonyms
KX2-391
dbp:tradename
Klisyri
dbp:unii
4
dbp:width
300
dbo:abstract
Tirbanibulin, sold under the brand name Klisyri, is a medication for the treatment of actinic keratosis (AKs) on the face or scalp. The most common side effects include local skin reactions, application site pruritus, and application site pain. Tirbanibulin was approved for medical use in the United States in December 2020, and in the European Union in July 2021. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It functions as a mitotic inhibitor by inhibiting tubulin polymerization and Src kinase signaling can be potentially effective in deferring the development of AKs to squamous cell carcinoma in situ. Tirbanibulin, vermarktet unter dem Markennamen Klisyri (Almirall), ist ein Arzneistoff zur Behandlung von aktinischer Keratose im Gesicht oder auf der Kopfhaut. Es wirkt als Mitosehemmer.
dbp:dailymedid
Tirbanibulin
dbp:legalEu
Rx-only
dbp:pdbLigand
DN0
prov:wasDerivedFrom
wikipedia-en:Tirbanibulin?oldid=1103124669&ns=0
dbo:wikiPageLength
11363
dbo:alternativeName
Klisyri
dbo:casNumber
897016-82-9
dbo:chEMBL
571546
dbo:drugbank
DB06137
dbo:fdaUniiCode
4V9848RS5G
dbo:kegg
D11691
dbo:pubchem
23635314
dbo:class
dbr:Microtubule_inhibitor
foaf:isPrimaryTopicOf
wikipedia-en:Tirbanibulin
Subject Item
dbr:Actinic_keratosis
dbo:wikiPageWikiLink
dbr:Tirbanibulin
Subject Item
dbr:ATC_code_D06
dbo:wikiPageWikiLink
dbr:Tirbanibulin
Subject Item
dbr:Klisyri
dbo:wikiPageWikiLink
dbr:Tirbanibulin
dbo:wikiPageRedirects
dbr:Tirbanibulin
Subject Item
wikipedia-en:Tirbanibulin
foaf:primaryTopic
dbr:Tirbanibulin